For example, NSCLC will develop resistance to EGFR tyrosine kinase inhibitors (TKIs) after a median of 10 to 14 months treatment and effective treatment has not been defined except Osimertinib for the T790M mutation (7, 8). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.